In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Good Will Marketing

Executive Summary

Abbott's new treatment for rheumatoid arthritis, Humira, is up against two drugs that between them generate $3 billion in sales annually. To help generate attention and distinguish the drug, Abbott is taking some unusual steps. It's offering to give drug away free to senior citizens who lack prescription drug benefits, and running general-awareness advertisements that talk about the disease rather than the drug. Contrary to conventional wisdom of what works in a crowded market, Abbott believes Humira's advantages are so compelling, that boosting the number of patients who go to see doctors will win market share for the drug--despite its coming third to market.
Advertisement

Related Content

Managing the Onslaught of Biotech Injectables
Can-Fite BioPharma Ltd.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel